The role of alemtuzumab in the development of secondary autoimmunity in multiple Sclerosis: a systematic review

被引:1
作者
Jimenez-Sanchez, Sofia [1 ,2 ]
Maksoud, Rebekah [2 ]
Eaton-Fitch, Natalie [2 ]
Marshall-Gradisnik, Sonya [2 ]
Broadley, Simon A. [1 ,3 ]
机构
[1] Griffith Univ, Sch Med & Dent, Gold Coast Campus, Southport, Qld, Australia
[2] Griffith Univ, Natl Ctr Neuroimmunol & Emerging Dis, Southport, Qld, Australia
[3] Gold Coast Univ Hosp, Dept Neurol, Southport, Qld, Australia
关键词
Multiple Sclerosis; Alemtuzumab; Secondary autoimmune disease; LYMPHOCYTE RECONSTITUTION; DEPLETION;
D O I
10.1186/s12974-024-03263-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundSecondary autoimmune disease (SAID) in the context of alemtuzumab treatment is one of the main safety concerns that may arise following administration in people with multiple sclerosis (pwMS). Contributing factors underlying this adverse event are not well understood. The purpose of this systematic review was to appraise the literature investigating the role of alemtuzumab in the development of SAID in pwMS following treatment and identify potential biomarkers/ risk factors that may be predictive of onset of this manifestation.MethodsRelevant publications were retrieved from PubMed, Embase, and Web of Science using a three-pronged search strategy containing the following keywords: "multiple sclerosis"; "alemtuzumab"; and "autoimmunity". Studies that fulfilled the specified eligibility criteria and investigated SAID development after alemtuzumab in pwMS were included in the final analysis.Results19 papers were included in the final review. Approximately, 47.92% of pwMS treated with alemtuzumab experienced SAID. A variety of biomarkers and risk factors were noted in the development of SAID, with a focus on immunological changes, including: increased homeostatic proliferation and T cell cycling, along with consistently elevated baseline serum IL-21 levels and thyroid autoantibodies. There was no significant association between known human leukocyte antigen (HLA) risk alleles, lymphocyte profile or dynamics and SAID development.ConclusionsWhile the mechanism underlying SAID following alemtuzumab is not fully understood, potential biomarkers and risk factors that may assist in elucidating mechanisms underlying this phenomenon have been documented in several independent studies. Following immunodepletion from alemtuzumab, an IL-21 driven increase in homeostatic proliferation and T cell cycling may disrupt tolerance mechanisms leading to an increase in the propensity toward alemtuzumab-induced autoimmunity. Further research is necessary to clarify the physiological changes after alemtuzumab therapy that trigger SAID in pwMS.
引用
收藏
页数:12
相关论文
共 50 条
[41]   Alemtuzumab and multiple sclerosis: therapeutic application [J].
Minagar, Alireza ;
Alexander, J. Steven ;
Sahraian, Mohammad Ali ;
Zivadinov, Robert .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (03) :421-429
[42]   The benefits and risks of alemtuzumab in multiple sclerosis [J].
Ontaneda, Daniel ;
Cohen, Jeffrey A. .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (03) :189-191
[43]   Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness [J].
Whiteside, D. ;
Barth, S. ;
Datta, A. ;
Trip, S. A. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 22 :139-140
[44]   Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data [J].
Coles, Alasdair J. ;
Jones, Joanne L. ;
Vermersch, Patrick ;
Traboulsee, Anthony ;
Bass, Ann D. ;
Boster, Aaron ;
Chan, Andrew ;
Comi, Giancarlo ;
Fernandez, Oscar ;
Giovannoni, Gavin ;
Kubala Havrdova, Eva ;
LaGanke, Christopher ;
Montalban, Xavier ;
Oreja-Guevara, Celia ;
Piehl, Fredrik ;
Wiendl, Heinz ;
Ziemssen, Tjalf .
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) :842-846
[45]   Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab [J].
Sottini, Alessandra ;
Quaresima, Virginia ;
Barbaro, Mose ;
Moiola, Lucia ;
Filippi, Massimo ;
Malentacchi, Maria ;
Capobianco, Marco ;
Puthenparampil, Marco ;
Gallo, Paolo ;
Cocco, Eleonora ;
Frau, Jessica ;
Zaffaroni, Mauro ;
Guaschino, Clara ;
Stampatori, Chiara ;
Mancinelli, Chiara ;
Brambilla, Laura ;
Clerici, Valentina Torri ;
Vianello, Marika ;
Vitetta, Francesca ;
Ferraro, Diana ;
Rosettani, Pamela ;
Danni, Maura Chiara ;
Conti, Marta ;
Grimoldi, Maria ;
Capra, Ruggero ;
Imberti, Luisa .
JOURNAL OF NEUROIMMUNOLOGY, 2023, 382
[46]   Role of Proangiogenic Factors in Immunopathogenesis of Multiple Sclerosis: A Systematic Review [J].
Hamid, Kabir Magaji ;
Mirshafiey, Abbas .
IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2016, 15 (01) :1-12
[47]   A Systematic Review on the Role of Arachidonic Acid Pathway in Multiple Sclerosis [J].
Hoxha, Malvina ;
Spahiu, Erila ;
Prendi, Emanuela ;
Zappacosta, Bruno .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2022, 21 (02) :160-187
[48]   Drug safety evaluation of alemtuzumab for multiple sclerosis [J].
Willis, Mark ;
Robertson, Neil P. .
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (08) :1115-1124
[49]   Sarcoidosis following alemtuzumab treatment for multiple sclerosis [J].
Willis, Mark D. ;
Hope-Gill, Ben ;
Flood-Page, Patrick ;
Joseph, Fady ;
Needham, Ed ;
Jones, Joanne ;
Coles, Alasdair ;
Robertson, Neil P. .
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (13) :1779-1782
[50]   Melanoma following treatment with alemtuzumab for multiple sclerosis [J].
Pace, A. A. ;
Zajicek, J. P. .
EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (04) :E70-E71